Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis-Reference-Cited by-同舟云学术

Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis

Published:2020-01-19 Issue:3 Volume:36 Page:477-482
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Cho Byoung Chul¹,Kim Dong-Wan²,Park Keunchil³,Lee Jong-Seok⁴,Yoo Seung Soo⁵,Kang Jin Hyoung⁶,Lee Sung Yong⁷,Kim Cheol Hyeon⁸,Jang Seung Hun⁹,Kim Young-Chul¹⁰,Yoon Hyoung-Kyu¹¹,Han Ji-Youn¹²,Kim Sang-We¹³

Affiliation:

1. Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Seoul, The Republic of Korea;

2. Department of Internal Medicine, Seoul National University Hospital, Seoul, The Republic of Korea;

3. Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, The Republic of Korea;

4. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoungnam, The Republic of Korea;

5. Department of Internal Medicine, Kyungpook National University Hospital, Daegu, The Republic of Korea;

6. Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, The Republic of Korea;

7. Department of Internal Medicine, Korea University Guro Hospital, Seoul, The Republic of Korea;

8. Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, The Republic of Korea;

9. Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, The Republic of Korea;

10. Lung Cancer Clinic, Hwasun Hospital, Chonnam National University Medical School, Jeonnam, The Republic of Korea;

11. Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, The Republic of Korea;

12. Center for Lung Cancer, National Cancer Center, Goyang, The Republic of Korea;

13. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, The Republic of Korea

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1676708

Reference26 articles.

1. International Agency for Research on Cancer. Cancer fact sheets: Lung cancer. Globocan [Internet]. Lyon (France): IARC. 2018 [cited 2018 Sep 20]. Available from: http://gco.iarc.fr/today/fact-sheets-cancers

2. Implications of key trials in advanced nonsmall cell lung cancer

3. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. NCCN Clinical Practice Guidelines in Oncology NSCLC (version 6) [Internet]. Plymouth (PA): NCCN. 2018 [cited 2018 Sep 14]. Available from: https://www.nccn.org/

5. New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study;Journal of Cancer Research and Clinical Oncology;2023-06-14

2. Advances in Lung Cancer Therapy;Cancers;2023-05-09

3. Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer;Cancer Research and Treatment;2023-01-15

4. Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea;Drugs - Real World Outcomes;2022-12-02

5. Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis;Thrombosis Research;2022-05